Given that cell–cell communication via Sema4D–Plexin-B1 signaling has been shown to be also functionally relevant in several other pathophysiological conditions such as diabetic retinopathy (52) and cancer (53, 54, 55, 56), it is tempting to speculate that the anti–Plexin-B1 antibody PLX7 could hold therapeutic potential in additional disease contexts. This evidence concerns the gene SEMA4D and cancer.